A Study of Continuous Oral Dosing of a Novel Antiandrogen MDV3100, in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Micro-Environment.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To explore the effect of treatment with MDV3100 on androgen signaling and expression of survival/escape pathways in the bone marrow
To explore the effect of treatment with MDV3100 on androgen signaling and expression of survival/escape pathways in the bone marrow of patients with castration-resistant metastatic prostate cancer in correlation with measures of antitumor activity to identify predictors of response or resistance to therapy.
9 weeks post baseline
No
United States: Food and Drug Administration
CRPC-MDA-1
NCT01091103
February 2010
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |